期刊文献+

甲氨蝶呤联合来氟米特或柳氮磺吡啶治疗类风湿关节炎的疗效 被引量:12

下载PDF
导出
摘要 目的:比较甲氨蝶呤联合来氟米特或柳氮磺吡啶治疗类风湿关节炎的疗效和不良反应。方法:40例活动性类风湿关节炎病人随机分为实验组和对照组,实验组用甲氨蝶呤(10mg/周)及来氟米特(20mg/d)治疗,对照组用甲氨蝶呤(10mg/周)及柳氮磺吡啶(2.0g/d)治疗,疗程为24周,对两种方案在12、24周时的疗效及观察指标进行评估。结果:实验组在12、24周时的总有效率分别为85%、95%,对照组为60%、70%,显示两组间差异有显著性。总副反应发生率两者差异无显著性。结论:甲氨蝶呤联合来氟米特治疗类风湿类节炎的疗效优于甲氨蝶呤联合柳氮磺吡啶,但前者副反应略大于后者。
出处 《实用医学杂志》 CAS 2006年第11期1301-1302,共2页 The Journal of Practical Medicine
  • 相关文献

参考文献6

  • 1BREEDVELD F C,DAYER J M.Leflunomide:mode of action in the treatment of rheumatoid arthritis[J].Ann Rheum Dis,2000,59 (11):841-849.
  • 2KREMER J M.Methotrexate and leflunomide:biochemical basis for combination therapy in the treatment of rheumatoid arthritis[J].Semin Arthritis Rheum,1999,29 (1):14-26.
  • 3WEINBLATT M E,KREMER J M,COBLY J S,et al.Pharmacokinetics,safety,and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis[J].Arthritis Rheum,1999,42(7):1322-1328.
  • 4PUNCHARD N A,BOSWELL D J,GREENFIELD S M,et al.The effects of sulphasalazine and metabolite on prostaglandin production by human mononuclear cells[J].Biochem Pharmacol,1992,43(11):2369-2376.
  • 5黄烽.对柳氮磺吡啶与甲氨蝶呤联合治疗类风湿关节炎的再思考[J].中华风湿病学杂志,2005,9(5):258-260. 被引量:9
  • 6GORONZY J J,MATTESON E L,FULBRIGHT J W,et al.Prognostic markers of radiographic progression in early rheumatoid arthritis[J].Arthritis Rheum,2004,50(1):43-54.

二级参考文献17

  • 1Case JP. Old and new drugs used in rheumatoid arthritis: a historical perspective (Part 1): the older drugs. Am J Ther, 2001,8: 123~143.
  • 2叶益新 张江林 黄烽.柳氮磺吡啶[A].见:蒋明 David Yu 林孝义 主编.中华风湿病学[C].北京:华夏出版社,2004.1746-1754.
  • 3Cronstein BN. Therapeutic cocktails for rheumatoid arthritis: the mixmaster's guide. Arthritis Rheum, 2004, 50: 2041-2043.
  • 4Jansen G, van der Heijden J, Oerlemans R, et al. Sulfasalazine is a potent inhibitor of the reduced folate carrier: implications for combination therapies with methotrexate in rheumatoid arthritis.Arthritis Rheum, 2004, 50: 2130-2139.
  • 5Jansen G, Scheper R J, Dijkmans BA. Multidrug resistance proteins in rheumatoid arthritis, role in disease-modifying antirheumatic drug efficacy and inflammatory processes: an overview.Scand J Rheumatol, 2003, 32: 325-336.
  • 6O'Dell JR, Leff R, Paulsen G, et al. Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a 2-year, randomized, double blind, placebo-controlled trial. Arthritis Rheum, 2002, 46: 1164-1170.
  • 7Landewe RB, Boers M, Verhoeven AC, et al. COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum, 2002,46: 347-356.
  • 8Van der Heijden J, de Jong MC, Dijkmans B, et al. Development of sulfasalazine resistance in human T cells induced expression of the multidrug resistance transporter ABCG2 (BCRP) and augmented production of TNF-α. Ann Rheum Dis, 2004, 63: 138-143.
  • 9Van der Heijden J, de Jong MC, Dijkmans B, et al. Acquired resistance of human T cells to sulfasalazine: stability of the resistant phenotype and sensitivity to non-related DMARD. Ann Rheum Dis, 2004,63:131-137.
  • 10Vezmar M, Georges E. Direct binding of chloroquine to the multi-drug resistance protein (MRP): possible role for MRP in chloroquine drug transport and resistance in tumor cells.Biochem Pharmacol, 1998, 56: 733-742.

共引文献8

同被引文献104

引证文献12

二级引证文献57

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部